Our findings indicate that, among patients with T2D receiving insulin therapy, the addition of GLP-1 RAs may confer substantial long-term benefits compared with DPP-4 inhibitors or sulfonylureas. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.